Pub Date : 2024-11-01DOI: 10.1016/j.reuma.2024.09.002
Sadettin Uslu , Gökhan Kabadayi , Pelin Teke Kısa , Tuba Yüce Inel , Zümrüt Arslan , Nur Arslan , Servet Akar , Fatos Onen , Ismail Sari
Objectives
Mutations in the α-galactosidase A (GLA) gene result in Fabry disease (FD), a rare metabolic condition. FD patients present with heterogeneous clinical manifestations, which may overlap with systemic diseases including familial Mediterranean fever (FMF). The aim of this study was to determine the frequency of FD in patients with mild and severe FMF and to prevent misdiagnosis by increasing clinicians’ awareness.
Methods
Based on Tel-Hashomer criteria, the study included a total of 91 FMF patients. Patients were divided into two groups according to the number of recurrent clinical episodes or failure to respond to maximum therapy: those with mild and severe forms of the disease. GLA gene mutations and α-GLA enzyme activity were assessed. Records of MEFV mutations, therapies and demographic characteristics were kept.
Results
FD testing was performed on a cohort of 91 FMF patients, 54.9% had mild FMF, 45.1% had severe FMF, and only one patient in the mild FMF subgroup tested positive for FD. The patient was a 39-year-old woman with a history of recurrent abdominal pain, distal limb pain and fever. She had low GLA enzyme activity and a heterozygous GLA gene mutation.
Conclusions
Our findings suggest that FD should be considered in the differential diagnosis of FMF, especially in individuals with unusual symptoms.
{"title":"Fabry disease in familial Mediterranean fever according to the severity of the disease","authors":"Sadettin Uslu , Gökhan Kabadayi , Pelin Teke Kısa , Tuba Yüce Inel , Zümrüt Arslan , Nur Arslan , Servet Akar , Fatos Onen , Ismail Sari","doi":"10.1016/j.reuma.2024.09.002","DOIUrl":"10.1016/j.reuma.2024.09.002","url":null,"abstract":"<div><h3>Objectives</h3><div>Mutations in the α-galactosidase A (GLA) gene result in Fabry disease (FD), a rare metabolic condition. FD patients present with heterogeneous clinical manifestations, which may overlap with systemic diseases including familial Mediterranean fever (FMF). The aim of this study was to determine the frequency of FD in patients with mild and severe FMF and to prevent misdiagnosis by increasing clinicians’ awareness.</div></div><div><h3>Methods</h3><div>Based on Tel-Hashomer criteria, the study included a total of 91 FMF patients. Patients were divided into two groups according to the number of recurrent clinical episodes or failure to respond to maximum therapy: those with mild and severe forms of the disease. GLA gene mutations and α-GLA enzyme activity were assessed. Records of MEFV mutations, therapies and demographic characteristics were kept.</div></div><div><h3>Results</h3><div>FD testing was performed on a cohort of 91 FMF patients, 54.9% had mild FMF, 45.1% had severe FMF, and only one patient in the mild FMF subgroup tested positive for FD. The patient was a 39-year-old woman with a history of recurrent abdominal pain, distal limb pain and fever. She had low GLA enzyme activity and a heterozygous GLA gene mutation.</div></div><div><h3>Conclusions</h3><div>Our findings suggest that FD should be considered in the differential diagnosis of FMF, especially in individuals with unusual symptoms.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 9","pages":"Pages 484-489"},"PeriodicalIF":1.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142578919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.reuma.2024.07.004
Lilia Andrade-Ortega , Daniel Xibillé-Friedmann , Dionicio A. Galarza-Delgado , Miguel Ángel Saavedra , José Alvarez-Nemegyei , Mary-Carmen Amigo-Castañeda , Hilda Fragoso-Loyo , María Vanessa Gordillo-Huerta , Fedra Irazoque-Palazuelos , Luis Javier Jara-Quezada† , Javier Merayo-Chalico , Margarita Portela-Hernández , Sandra Sicsik-Ayala , Carlos Abud-Mendoza , Deshire Alpizar-Rodriguez , José Luis Amaya-Estrada , Yaneth R. Barragán-Navarro , Sandra M. Carrillo-Vázquez , Zully Castro-Colín , Luis Javier Cruz-Álvarez , Leonor A. Barile-Fabris
Herein we present the update for the Mexican Guidelines for the Treatment of Systemic Lupus Erythematosus. It involves the participation of several experts along the country, following the GRADE system.
We included aspects regarding vaccines, pregnancy and cardiovascular risk which were not presented in the previous guidelines in 2017.
{"title":"Guías de Práctica Clínica para el tratamiento del lupus eritematoso sistémico del Colegio Mexicano de Reumatología. Actualización 2024","authors":"Lilia Andrade-Ortega , Daniel Xibillé-Friedmann , Dionicio A. Galarza-Delgado , Miguel Ángel Saavedra , José Alvarez-Nemegyei , Mary-Carmen Amigo-Castañeda , Hilda Fragoso-Loyo , María Vanessa Gordillo-Huerta , Fedra Irazoque-Palazuelos , Luis Javier Jara-Quezada† , Javier Merayo-Chalico , Margarita Portela-Hernández , Sandra Sicsik-Ayala , Carlos Abud-Mendoza , Deshire Alpizar-Rodriguez , José Luis Amaya-Estrada , Yaneth R. Barragán-Navarro , Sandra M. Carrillo-Vázquez , Zully Castro-Colín , Luis Javier Cruz-Álvarez , Leonor A. Barile-Fabris","doi":"10.1016/j.reuma.2024.07.004","DOIUrl":"10.1016/j.reuma.2024.07.004","url":null,"abstract":"<div><div>Herein we present the update for the Mexican Guidelines for the Treatment of Systemic Lupus Erythematosus. It involves the participation of several experts along the country, following the GRADE system.</div><div>We included aspects regarding vaccines, pregnancy and cardiovascular risk which were not presented in the previous guidelines in 2017.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 9","pages":"Pages 490-510"},"PeriodicalIF":1.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142578920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.reuma.2024.07.003
Deysi Andrea Hernández-Rivero , Lisette Bazán-Rodríguez , María del Pilar Cruz-Domínguez , Gabriela Medina , Ana Lilia Peralta Amaro , Olga Vera-Lastra
Inclusion body myositis is a idiopathic inflammatory myopathy characterized by muscle weakness and dysphagia, with muscle biopsy showing inflammation and rimmed vacuoles. We present the case of a patient who was diagnosed with polymyositis but due to lack of response to treatment, a new biopsy revealed inclusion body myositis.
{"title":"Miositis por cuerpos de inclusión: informe de un caso de diagnóstico tardío","authors":"Deysi Andrea Hernández-Rivero , Lisette Bazán-Rodríguez , María del Pilar Cruz-Domínguez , Gabriela Medina , Ana Lilia Peralta Amaro , Olga Vera-Lastra","doi":"10.1016/j.reuma.2024.07.003","DOIUrl":"10.1016/j.reuma.2024.07.003","url":null,"abstract":"<div><div>Inclusion body myositis is a idiopathic inflammatory myopathy characterized by muscle weakness and dysphagia, with muscle biopsy showing inflammation and rimmed vacuoles. We present the case of a patient who was diagnosed with polymyositis but due to lack of response to treatment, a new biopsy revealed inclusion body myositis.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 9","pages":"Pages 511-512"},"PeriodicalIF":1.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142578921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.reuma.2024.06.004
Natalia de la Torre Rubio, Jose Campos Esteban, José Luis Andréu Sánchez, Jesús Sanz Sanz
{"title":"Prevalencia del entesofito occipital en enfermedades reumáticas inflamatorias y no inflamatorias","authors":"Natalia de la Torre Rubio, Jose Campos Esteban, José Luis Andréu Sánchez, Jesús Sanz Sanz","doi":"10.1016/j.reuma.2024.06.004","DOIUrl":"10.1016/j.reuma.2024.06.004","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 9","pages":"Pages 513-514"},"PeriodicalIF":1.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142578922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Evaluate response to treatment and progression to rheumatoid arthritis (RA) in patients with fibromyalgia (FM) associated with elevated rheumatoid factor (RF).
Material and methods
Prospective cohort study. The sample consisted of 124 patients with FM: 62 with high RF (> 20 U/ml) and 62 with negative RF (0-20 U/ml). All patients were evaluated using FM treatment improvement score (FIQR) and progression to RA according to EULAR/ACR 2010 criteria at 6 and 12 months. Pearson's χ2 test for homogeneity was used to relate variables of improvement to FM treatment and progression to RA.
Results
The response to treatment was lower in the high RF group (24 and 20 patients improved at 6 and 12 months, respectively, compared to 45 and 38 patients in the negative RF group), with a significant difference. Progression to rheumatoid arthritis was similar in both groups (5 in the high RF group and 4 in the negative RF group), with a non-significant relationship.
Conclusions
FM with elevated RF is associated with a poor therapeutic response but not with progression to RA.
{"title":"La fibromialgia con factor reumatoide elevado se asocia a mala respuesta terapéutica pero no con progresión a artritis reumatoide. Estudio de cohortes prospectivo","authors":"Freddy Liñán Ponce, Juan Leiva Goicochea, David Sevilla Rodríguez, Elmer Hidalgo Bravo, Ginna Obregón Atanacio, Inés Loyola Macalapú, Paola Jáuregui Rojas, Jackeline Yampufe Canani","doi":"10.1016/j.reuma.2024.06.005","DOIUrl":"10.1016/j.reuma.2024.06.005","url":null,"abstract":"<div><h3>Objective</h3><div>Evaluate response to treatment and progression to rheumatoid arthritis (RA) in patients with fibromyalgia (FM) associated with elevated rheumatoid factor (RF).</div></div><div><h3>Material and methods</h3><div>Prospective cohort study. The sample consisted of 124 patients with FM: 62 with high RF (><!--> <!-->20<!--> <!-->U/ml) and 62 with negative RF (0-20<!--> <!-->U/ml). All patients were evaluated using FM treatment improvement score (FIQR) and progression to RA according to EULAR/ACR 2010 criteria at 6 and 12 months. Pearson's χ<sup>2</sup> test for homogeneity was used to relate variables of improvement to FM treatment and progression to RA.</div></div><div><h3>Results</h3><div>The response to treatment was lower in the high RF group (24 and 20 patients improved at 6 and 12<!--> <!-->months, respectively, compared to 45 and 38 patients in the negative RF group), with a significant difference. Progression to rheumatoid arthritis was similar in both groups (5 in the high RF group and 4 in the negative RF group), with a non-significant relationship.</div></div><div><h3>Conclusions</h3><div>FM with elevated RF is associated with a poor therapeutic response but not with progression to RA.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 9","pages":"Pages 459-462"},"PeriodicalIF":1.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142578915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01DOI: 10.1016/j.reuma.2024.04.004
Hakan Apaydin , Serdar Can Güven , Rezan Koçak Ulucaköy , Hakan Babaoğlu , Esra Kayacan Erdoğan , Kevser Orhan , Berkan Armağan
Aims
Evidence evaluating the association between pre-frailty and frailty, and risk of adverse health outcomes in patients with Behçet's syndrome (BS) is limited in the literature. The aim of this study was to characterize the prevalence of frailty and associated factors in a single-centre cohort of patients with BS.
Methods
Based on the International Study Group's criteria, this was a monocentric cross-sectional study of BS patients. The Fried frailty criteria were used to define frailty. The Turkish version of the Behçet's Disease Current Activity Form was used to measure the disease activity of BS. Damage index was assessed with the Behçet's Syndrome Overall Damage Index.
Results
Forty-four patients were enrolled. According to Fried frailty criteria, patients were classified as 13.6% frail, 59% pre-frail, and 27.2% robust, respectively. Compared to pre-frail and robust patients, frail patients had higher levels of inflammatory markers at the time of diagnosis. CRP levels at time of diagnosis and at the last visit were higher in the frail group than in the pre-frail and robust groups (p = 0.039 and p = 0.023, respectively). When active drugs for BS were evaluated, systemic glucocorticoid (50%, p = 0.030) and cyclophosphamide (33.3%, p = 0.006) treatments were higher in the frail group.
Conclusions
Frailty and pre-frailty are commonly detected even in younger patients with BS. Inflammation can be described as potential determinants of frailty status.
{"title":"Frailty assessment in patients with Behçet's syndrome: A cross-sectional monocentric study","authors":"Hakan Apaydin , Serdar Can Güven , Rezan Koçak Ulucaköy , Hakan Babaoğlu , Esra Kayacan Erdoğan , Kevser Orhan , Berkan Armağan","doi":"10.1016/j.reuma.2024.04.004","DOIUrl":"10.1016/j.reuma.2024.04.004","url":null,"abstract":"<div><h3>Aims</h3><div>Evidence evaluating the association between pre-frailty and frailty, and risk of adverse health outcomes in patients with Behçet's syndrome (BS) is limited in the literature. The aim of this study was to characterize the prevalence of frailty and associated factors in a single-centre cohort of patients with BS.</div></div><div><h3>Methods</h3><div>Based on the International Study Group's criteria, this was a monocentric cross-sectional study of BS patients. The Fried frailty criteria were used to define frailty. The Turkish version of the Behçet's Disease Current Activity Form was used to measure the disease activity of BS. Damage index was assessed with the Behçet's Syndrome Overall Damage Index.</div></div><div><h3>Results</h3><div>Forty-four patients were enrolled. According to Fried frailty criteria, patients were classified as 13.6% frail, 59% pre-frail, and 27.2% robust, respectively. Compared to pre-frail and robust patients, frail patients had higher levels of inflammatory markers at the time of diagnosis. CRP levels at time of diagnosis and at the last visit were higher in the frail group than in the pre-frail and robust groups (<em>p</em> <!-->=<!--> <!-->0.039 and <em>p</em> <!-->=<!--> <!-->0.023, respectively). When active drugs for BS were evaluated, systemic glucocorticoid (50%, <em>p</em> <!-->=<!--> <!-->0.030) and cyclophosphamide (33.3%, <em>p</em> <!-->=<!--> <!-->0.006) treatments were higher in the frail group.</div></div><div><h3>Conclusions</h3><div>Frailty and pre-frailty are commonly detected even in younger patients with BS. Inflammation can be described as potential determinants of frailty status.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 8","pages":"Pages 409-415"},"PeriodicalIF":1.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142357999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01DOI: 10.1016/j.reuma.2024.05.007
José María Álvaro-Gracia Álvaro , Petra Díaz del Campo Fontecha , José Luis Andréu Sánchez , Alejandro Balsa Criado , Rafael Cáliz Cáliz , Isabel Castrejón Fernández , Hèctor Corominas , José A. Gómez Puerta , Sara Manrique Arija , Natalia Mena Vázquez , Ana Ortiz García , Chamaida Plasencia Rodríguez , Lucía Silva Fernández , Jesús Tornero Molina
Objective
To update the consensus document of the Spanish Society of Rheumatology (SER) regarding the use of targeted biological and synthetic therapies in rheumatoid arthritis (RA) with the aim of assisting clinicians in their therapeutic decisions.
Methods
A panel of 13 experts was assembled through an open call by SER. We employed a mixed adaptation-elaboration-update methodology starting from the 2015 Consensus Document of the Spanish Society of Rheumatology on the use of biological therapies in RA. Starting with systematic reviews (SR) of recommendations from EULAR 2019, American College of Rheumatology 2021, and GUIPCAR 2017, we updated the search strategies for the PICO questions of GUIPCAR. An additional SR was conducted on demyelinating disease in relation to targeted biological and synthetic therapies. Following the analysis of evidence by different panelists, consensus on the wording and level of agreement for each recommendation was reached in a face-to-face meeting.
Results
The panel established 5 general principles and 15 recommendations on the management of RA. These encompassed crucial aspects such as the importance of early treatment, therapeutic goals in RA, monitoring frequency, the use of glucocorticoids, the application of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), biological DMARDs (bDMARDs), and targeted synthetic DMARDs. Additionally, recommendations on dose reduction of these drugs in stable patients were included. This update also features recommendations on the use of bDMARDs and Janus Kinase inhibitors in some specific clinical situations, such as patients with lung disease, a history of cancer, heart failure, or demyelinating disease.
Conclusions
This update provides recommendations on key aspects in the management of RA using targeted biological and synthetic therapies.
目的更新西班牙风湿病学会（SER）关于类风湿性关节炎（RA）使用靶向生物和合成疗法的共识文件，以协助临床医生做出治疗决策。方法通过西班牙风湿病学会的公开征集，组建了一个由 13 位专家组成的小组。我们从 2015 年西班牙风湿病学会关于在 RA 中使用生物疗法的共识文件开始，采用了改编-阐述-更新的混合方法。从 EULAR 2019、American College of Rheumatology 2021 和 GUIPCAR 2017 建议的系统回顾（SR）开始，我们更新了 GUIPCAR PICO 问题的检索策略。我们还就脱髓鞘疾病与靶向生物和合成疗法的关系进行了额外的SR研究。不同的专家组成员对证据进行分析后，在一次面对面的会议上就每项建议的措辞和一致程度达成了共识。这些建议包括早期治疗的重要性、RA 的治疗目标、监测频率、糖皮质激素的使用、常规合成改善病情抗风湿药（csDMARDs）、生物 DMARDs（bDMARDs）和靶向合成 DMARDs 的应用等重要方面。此外，还包括对病情稳定的患者减少这些药物剂量的建议。本更新版还就在某些特殊临床情况下使用生物DMARDs和Janus激酶抑制剂提出了建议，如患有肺部疾病、癌症病史、心力衰竭或脱髓鞘疾病的患者。结论本更新版就使用靶向生物和合成疗法治疗RA的关键方面提出了建议。
{"title":"Actualización del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas y sintéticas dirigidas en la artritis reumatoide","authors":"José María Álvaro-Gracia Álvaro , Petra Díaz del Campo Fontecha , José Luis Andréu Sánchez , Alejandro Balsa Criado , Rafael Cáliz Cáliz , Isabel Castrejón Fernández , Hèctor Corominas , José A. Gómez Puerta , Sara Manrique Arija , Natalia Mena Vázquez , Ana Ortiz García , Chamaida Plasencia Rodríguez , Lucía Silva Fernández , Jesús Tornero Molina","doi":"10.1016/j.reuma.2024.05.007","DOIUrl":"10.1016/j.reuma.2024.05.007","url":null,"abstract":"<div><h3>Objective</h3><div>To update the consensus document of the Spanish Society of Rheumatology (SER) regarding the use of targeted biological and synthetic therapies in rheumatoid arthritis (RA) with the aim of assisting clinicians in their therapeutic decisions.</div></div><div><h3>Methods</h3><div>A panel of 13 experts was assembled through an open call by SER. We employed a mixed adaptation-elaboration-update methodology starting from the 2015 Consensus Document of the Spanish Society of Rheumatology on the use of biological therapies in RA. Starting with systematic reviews (SR) of recommendations from EULAR 2019, American College of Rheumatology 2021, and GUIPCAR 2017, we updated the search strategies for the PICO questions of GUIPCAR. An additional SR was conducted on demyelinating disease in relation to targeted biological and synthetic therapies. Following the analysis of evidence by different panelists, consensus on the wording and level of agreement for each recommendation was reached in a face-to-face meeting.</div></div><div><h3>Results</h3><div>The panel established 5 general principles and 15 recommendations on the management of RA. These encompassed crucial aspects such as the importance of early treatment, therapeutic goals in RA, monitoring frequency, the use of glucocorticoids, the application of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), biological DMARDs (bDMARDs), and targeted synthetic DMARDs. Additionally, recommendations on dose reduction of these drugs in stable patients were included. This update also features recommendations on the use of bDMARDs and Janus Kinase inhibitors in some specific clinical situations, such as patients with lung disease, a history of cancer, heart failure, or demyelinating disease.</div></div><div><h3>Conclusions</h3><div>This update provides recommendations on key aspects in the management of RA using targeted biological and synthetic therapies.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 8","pages":"Pages 423-439"},"PeriodicalIF":1.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141688982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01DOI: 10.1016/j.reuma.2024.05.002
Pedro Alfonso Domínguez Vera , Luis Carrasco Páez
Background and objective
The use of SYmptomatic Slow-Acting Drugs for Osteoarthritis (SYSADOA) in the treatment of osteoarthritis (OA) has been a topic of debate in the scientific community and public entities regarding their public financing in Spain. The objective of this study was to describe and analyze the main positions of media outlets, public entities, regarding the use and financing of SYSADOA in Spain.
Methods
A qualitative and quantitative analysis of the content regarding the use and financing of SYSADOA was conducted in general media outlets (El País, El Mundo, La Vanguardia, ABC, and 20minutos), public statements, and Twitter® publications.
Results
A total of 15 articles in general media outlets, 872 tweets, and 7 public entity statements were identified. Mostly, media outlets (91%) and social media platforms (78%) exhibited a favorable trend towards funding.
Discussion and conclusions
The use of SYSADOA in OA patients continues to be controversial in the scientific community. However, there is consensus among patient associations in favor of public funding and use as a treatment for OA patients.
背景和目的在西班牙，骨关节炎慢作用药物 SYSADOA（SYmptomatic Slow-Acting Drugs for Osteoarthritis）在治疗骨关节炎（OA）方面的应用一直是科学界和公共实体就其公共融资问题争论不休的话题。本研究旨在描述和分析媒体、公共实体对西班牙使用和资助 SYSADOA 的主要立场。研究方法对一般媒体（El País、El Mundo、La Vanguardia、ABC 和 20minutos）、公共声明和 Twitter® 出版物中有关 SYSADOA 使用和资助的内容进行了定性和定量分析。结果共发现 15 篇一般媒体文章、872 条微博和 7 份公共实体声明。大多数媒体（91%）和社交媒体平台（78%）对资助表现出了积极的趋势。讨论与结论在 OA 患者中使用 SYSADOA 在科学界仍存在争议。然而，患者协会已达成共识，赞成公共资助并将其用作治疗 OA 患者的方法。
{"title":"Controversia en el uso y en la financiación de SYSADOA para la osteoartritis en España: un análisis del debate científico-social en los medios de comunicación","authors":"Pedro Alfonso Domínguez Vera , Luis Carrasco Páez","doi":"10.1016/j.reuma.2024.05.002","DOIUrl":"10.1016/j.reuma.2024.05.002","url":null,"abstract":"<div><h3>Background and objective</h3><div>The use of SYmptomatic Slow-Acting Drugs for Osteoarthritis (SYSADOA) in the treatment of osteoarthritis (OA) has been a topic of debate in the scientific community and public entities regarding their public financing in Spain. The objective of this study was to describe and analyze the main positions of media outlets, public entities, regarding the use and financing of SYSADOA in Spain.</div></div><div><h3>Methods</h3><div>A qualitative and quantitative analysis of the content regarding the use and financing of SYSADOA was conducted in general media outlets (<em>El País</em>, <em>El Mundo, La Vanguardia, ABC,</em> and <em>20minutos</em>), public statements, and Twitter® publications.</div></div><div><h3>Results</h3><div>A total of 15 articles in general media outlets, 872 tweets, and 7 public entity statements were identified. Mostly, media outlets (91%) and social media platforms (78%) exhibited a favorable trend towards funding.</div></div><div><h3>Discussion and conclusions</h3><div>The use of SYSADOA in OA patients continues to be controversial in the scientific community. However, there is consensus among patient associations in favor of public funding and use as a treatment for OA patients.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 8","pages":"Pages 416-422"},"PeriodicalIF":1.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141695971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01DOI: 10.1016/j.reuma.2024.06.006
Jose Luis Vicente-Escudero
The presence of anxiety and depression symptoms in patients with lupus is common, and some research reports that psychological interventions can reduce them, therefore we conducted a systematic review and meta-analysis of the efficacy of psychological interventions in adults with systemic lupus erythematosus. Randomized and non-randomized clinical trials with adult population diagnosed with lupus, treated with psychological intervention, and compared with similar groups were selected. Several databases were searched in July 2023. Fourteen studies were included in the meta-analysis, with moderate effect sizes for anxiety and depression in group intervention modalities. Factors such as percentage of sample with lupus, gender, medication, and interventions with relaxation components influenced the results. Group psychological intervention programs are effective in reducing symptoms in patients with lupus, although further research on treatment modulating variables is needed.
{"title":"Efficacy of psychological interventions to reduce anxiety and depression in patients with lupus. A systematic review and meta-analysis","authors":"Jose Luis Vicente-Escudero","doi":"10.1016/j.reuma.2024.06.006","DOIUrl":"10.1016/j.reuma.2024.06.006","url":null,"abstract":"<div><div>The presence of anxiety and depression symptoms in patients with lupus is common, and some research reports that psychological interventions can reduce them, therefore we conducted a systematic review and meta-analysis of the efficacy of psychological interventions in adults with systemic lupus erythematosus. Randomized and non-randomized clinical trials with adult population diagnosed with lupus, treated with psychological intervention, and compared with similar groups were selected. Several databases were searched in July 2023. Fourteen studies were included in the meta-analysis, with moderate effect sizes for anxiety and depression in group intervention modalities. Factors such as percentage of sample with lupus, gender, medication, and interventions with relaxation components influenced the results. Group psychological intervention programs are effective in reducing symptoms in patients with lupus, although further research on treatment modulating variables is needed.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 8","pages":"Pages 440-451"},"PeriodicalIF":1.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142357984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号